Skip to main content
As published for the week of Monday, March 02, 2015

  • Cover Story: Product Development: Prevention by the pound

    Why Janssen created stand-alone group to stop diseases from starting

    By Susan Schaeffer, Editor

    Both the greatest promise and the biggest challenge in treating progressive diseases lie in intervening early, before disease processes become too complex to intercept and damage to tissues and systems becomes irreversible. In many settings, basic and translational research are beginning to reveal the molecular drivers of the transition from healthy to disease states, offering the tantalizing prospect of cutting these processes off before illness even begins.

    There have been numerous successful examples of intercepting disease with pharmaceuticals in cardiovascular disease, and several companies have an interception program here or there in other disease areas. But for the most part the pharmaceutical R&D apparatus isn't set up for large scale, rapid development of interventions that can interrupt the transition from health to disease. Nor is the regulatory system set up to run trials in this setting in a meaningful time frame and at a reasonable cost.

    Full Article

Money Raised in 2015

Last week, the biotech industry raised $902 million, bringing to $16.5 billion the total raised year-to-date. In 2014, a total of $54.5 billion was raised, including $21.5 billion in debt, $11.1 billion in follow-ons, $3.9 billion in PIPEs and other equity, $9 billion in IPOs, and $9 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial